Acute Myeloid Leukemia (AML): Treatment Options, including BMT, Care and Support
Sponsored jointly by the National Marrow Donor Program®/Be The Match® and The Leukemia & Lymphoma Society® (LLS).
Release date: July 14, 2017
Expiration date: December 14, 2018
In the United States, approximately 21,380 people will be diagnosed with acute myeloid leukemia (AML) in 2017.1
Timely access to information on treatment options can empower patients to actively participate in their treatment plan. In this free continuing education webinar, speakers will address how molecular testing at diagnosis can help to inform treatment recommendations; the risks and benefits of treatment options for patients with AML; the impact of timely referral for blood and marrow transplant (BMT) on outcomes for patients with high-risk AML; and unique considerations for older adults.
The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with AML. Attendees are encouraged to submit questions for a Q&A discussion.
Hematology oncology and BMT nurses; hematology oncology and BMT social workers at intermediate to advanced levels of practice, experience and licensure; transplant center coordinators; payer case managers and other allied health professionals.
- Identify diagnostic tests included in AML panels, including the role of cytogenetics and molecular analysis.
- Describe risk stratification for treatment planning.
- Identify approved and emerging treatment options and the role of clinical trials for the treatment of AML.
- Explain the impact of timely blood and marrow transplantation (BMT) referral.
- List programs and resources to support patients with acute myeloid leukemia and their caregivers.
Daniel A. Pollyea, MD, MS
Associate Professor, University of Colorado School of Medicine
Clinical Director of Leukemia Services
Elaina V. Preston, MPH, MSHS, PA-C
Physician Assistant, Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
Accreditation and certification
Nurses: The National Marrow Donor Program is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (COA).
Up to 1.25 contact hours may be claimed for this educational activity.
Social workers: The Leukemia & Lymphoma Society (LLS), provider #1105 is approved as a provider for social work continuing education by the Association of Social Work Boards www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/2014 - 12/2017. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval.
LLS is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program.
Social workers will receive 1.25 clinical continuing education hours for this activity.
Upon completion of this program and submission of the CE activity evaluation, a certificate of completion will be issued to you via email within 30 days.
Medical technologists: The NMDP is approved as a provider of continuing education in the clinical laboratory sciences through the ASCLS PACE Program. ASCLS PACE® 1861 International Drive, Suite 200, McLean, VA 22102.
Up to 1.00 contact hours may be claimed for program #115-021-17.
All other health professionals requesting continuing education credit for this activity will be issued a Certificate of Attendance.
Assistance for people with disabilities, grievances, questions or for more information, please call (800) 955-4572.
Participants must complete and submit the evaluation for the activity in order to receive a continuing education certificate or a certificate of completion.
Certificates will be issued via email with 30 days.
If you have any questions regarding this activity, email email@example.com.
1 SEER Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/amyl.html
Sponsored jointly by: